Medicare Enrolled
Dr. Revathi Angitapalli, M.D.
Hematology & Oncology · Arlington, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Angitapalli from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Angitapalli? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Angitapalli
Dr. Revathi Angitapalli is a hematology & oncology in Arlington, TX, with 17 years in practice. Based on federal Medicare data, Dr. Angitapalli performed 56,079 Medicare services across 1,264 unique beneficiaries.
Between the years covered by Open Payments, Dr. Angitapalli received a total of $17,949 from 91 pharmaceutical and/or device companies across 728 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Angitapalli is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice▲ Top 16% volume in TX$ $17,949 industry payments
Medicare Practice Summary
Medicare Utilization ↗56,079
Medicare services
Top 16% in TX for hematology & oncology
1,264
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,299 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 35,250 | $1 | $3 |
| Anti-nausea injection (fosaprepitant) | 11,850 | $0 | $5 |
| Dexamethasone injection (steroid) | 2,176 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 1,740 | $18 | $40 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,110 | $1 | $52 |
| Office visit, established patient (30-39 min) | 474 | $93 | $275 |
| Office visit, established patient, complex (40-54 min) | 437 | $131 | $350 |
| Injection of additional new drug or substance into vein | 415 | $12 | $70 |
| Injection, zoledronic acid, 1 mg | 367 | $7 | $300 |
| COVID-19 test, self-administered | 364 | $12 | $30 |
| Administration of chemotherapy into vein, 1 hour or less | 302 | $101 | $412 |
| Drug injection, under skin or into muscle | 188 | $11 | $60 |
| Injection, triptorelin pamoate, 3.75 mg | 185 | $295 | $1,000 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 154 | $23 | $100 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 150 | $48 | $190 |
| Office visit, established patient (20-29 min) | 143 | $65 | $175 |
| Administration of chemotherapy into vein, each additional hour | 123 | $22 | $93 |
| Injection, diphenhydramine hcl, up to 50 mg | 112 | $1 | $10 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 77 | $48 | $160 |
| Administration of additional new drug or substance into vein, 1 hour or less | 74 | $51 | $202 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 67 | $26 | $105 |
| Ct scan of chest with contrast | 61 | $53 | $401 |
| CT scan of abdomen and pelvis with contrast | 48 | $175 | $681 |
| Comprehensive metabolic blood panel | 43 | $10 | $50 |
| Hospital follow-up visit, high complexity | 36 | $93 | $250 |
| Advance care planning consultation, first 30 min | 31 | $65 | $250 |
| New patient office visit, complex (60-74 min) | 30 | $164 | $500 |
| New patient office visit (45-59 min) | 27 | $126 | $400 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 25 | $1,143 | $4,069 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 20 | $106 | $450 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
63.4% high complexity
33.5% medium
3.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,949
Total received (2018-2024)
Avg $2,564/year across 7 years
Top 22% in TX for hematology & oncology
91
Companies
728
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,406 (91.4%)
Other
Charitable contributions, space rental, and other categories
$1,321 (7.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$222 (1.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,781
2023$2,175
2022$597
2021$486
2020$4,010
2019$3,563
2018$3,337
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Roche Products Limited
$2,214
Novartis Pharmaceuticals Corporation
$1,983
PFIZER INC.
$849
Amgen Inc.
$668
AstraZeneca Pharmaceuticals LP
$609
Celgene Corporation
$583
Lilly USA, LLC
$525
E.R. Squibb & Sons, L.L.C.
$525
Astellas Pharma US Inc
$518
Janssen Biotech, Inc.
$504
Daiichi Sankyo Inc.
$459
Genentech USA, Inc.
$446
Seagen Inc.
$329
Merck Sharp & Dohme Corporation
$320
Gilead Sciences, Inc.
$314
NOVARTIS PHARMACEUTICALS CORPORATION
$299
Incyte Corporation
$297
Clovis Oncology, Inc.
$290
GENZYME CORPORATION
$282
Takeda Pharmaceuticals U.S.A., Inc.
$279
Eisai Inc.
$273
Exelixis Inc.
$227
Heron Therapeutics, Inc.
$222
Taiho Oncology, Inc.
$219
Merck Sharp & Dohme LLC
$214
EMD Serono, Inc.
$202
Bayer HealthCare Pharmaceuticals Inc.
$200
Regeneron Healthcare Solutions, Inc.
$196
TerSera Therapeutics LLC
$190
GlaxoSmithKline, LLC.
$187
Spectrum Pharmaceuticals Inc.
$183
Boehringer Ingelheim Pharmaceuticals, Inc.
$176
PUMA BIOTECHNOLOGY, INC.
$175
Sirtex Medical Inc
$169
Verastem, Inc.
$163
Kite Pharma, Inc.
$136
Karyopharm Therapeutics Inc.
$116
Pharmacosmos Therapeutics Inc.
$116
Rigel Pharmaceuticals, Inc.
$113
Pharmacyclics LLC, An AbbVie Company
$111
Stemline Therapeutics Inc.
$105
ABBVIE INC.
$103
Puma Biotechnology, Inc.
$100
Sun Pharmaceutical Industries Inc.
$98
Foundation Medicine, Inc.
$92
JAZZ PHARMACEUTICALS INC.
$81
ARRAY BIOPHARMA INC
$72
Seattle Genetics, Inc.
$71
Coherus Biosciences Inc.
$67
Dendreon Pharmaceuticals LLC
$66
AbbVie, Inc.
$60
EISAI INC.
$59
INSYS Therapeutics Inc
$58
TESARO, Inc.
$55
Deciphera Pharmaceuticals Inc.
$54
SERVIER PHARMACEUTICALS LLC
$48
MorphoSys, US Inc.
$48
BeiGene USA, Inc.
$47
Adaptive Biotechnologies Corporation
$47
Tactile Systems Technology Inc
$46
Janssen Scientific Affairs, LLC
$45
Genmab U.S., Inc.
$40
Kyowa Kirin, Inc.
$37
Dova Pharmaceuticals
$36
MEDIVATION FIELD SOLUTIONS LLC
$36
PharmaEssentia USA Corporation
$35
Ipsen Biopharmaceuticals, Inc
$35
Bayer Healthcare Pharmaceuticals Inc.
$32
Lexicon Pharmaceuticals, Inc.
$29
Mirati Therapeutics, Inc.
$28
SpringWorks Therapeutics, Inc.
$23
SOBI, INC
$22
Blueprint Medicines Corporation
$21
MENARINI SILICON BIOSYSTEMS, INC.
$21
Immunocore Limited
$21
ImmunoGen, Inc.
$20
Jazz Pharmaceuticals Inc.
$19
Secura Bio, Inc.
$18
Acrotech Biopharma Inc.
$18
Shire North American Group Inc
$17
TAIHO ONCOLOGY, INC.
$17
Boston Scientific Corporation
$16
Mylan Institutional Inc.
$14
Organon Llc
$13
Helsinn Therapeutics (U.S.), Inc.
$13
Acrotech Biopharma LLC
$12
Acceleron Pharma, Inc.
$12
Teva Pharmaceuticals USA, Inc.
$12
Array BioPharma Inc.
$11
Epizyme, Inc.,
$11
Janssen Pharmaceuticals, Inc
$10
Top 3 companies account for 28.1% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Alecensa · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRUKINSA · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CALQUENCE · CINVANTI · CYRAMZA · Cabometyx · Cellsearch · Copiktra · DARZALEX · DAURISMO · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Elahere · Enhertu · Epkinly · Erleada · FARYDAK · FRUZAQLA · Flexitouch Plus · Fulphila · GAZYVA · GILOTRIF · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFUGEM · INJECTAFER · INLYTA · INQOVI · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lupron · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nerlynx · Neulasta · Non-Covered Product · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONTRUZANT · OPDIVO · Odomzo · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · ROLVEDON · RYDAPT · Reblozyl · Revlimid · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUSTOL · SUTENT · SYNDROS · Stivarga · TABRECTA · TAGRISSO · TALZENNA · TASIGNA · TAXOTERE · TAZVERIK · TECENTRIQ · TEPMETKO · TEVIMBRA · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tecentriq · Tibsovo · Tivdak · Trodelvy · Udenyca · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · Vanflyta · Varithena Administration Pack · Venclexta · Vyloy · XALKORI · XGEVA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (91%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $32 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
133
Per 100K population
6.2
County median income
$81,905
Nearest hospital
MEDICAL CITY ARLINGTON
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Angitapalli is a mixed practice specialist, with above-average Medicare volume (top 16% in TX), and low-engagement industry engagement, with 17 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Angitapalli experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Angitapalli performed 35,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Angitapalli receive payments from pharmaceutical companies?
Yes. Dr. Angitapalli received a total of $17,949 from 91 companies across 728 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Angitapalli's costs compare to other hematology & oncologys in Arlington?
Dr. Angitapalli's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Angitapalli) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Arlington
Browse hematology & oncologys in Arlington ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Roche Products Limited Payments to Doctors
See all physicians who received payments from Roche Products Limited.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology